# ![@petitnong_ Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1350631692755628034.png) @petitnong_ petitnong

petitnong posts on X about $ibrx, saudi arabia, in the, market cap the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1350631692755628034/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1350631692755628034/c:line/m:interactions.svg)

- [--] Week [------] -44%
- [--] Months [-------] +388%
- [--] Year [-------] +478%

### Mentions: [--] [#](/creator/twitter::1350631692755628034/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1350631692755628034/c:line/m:posts_active.svg)

- [--] Week [--] -6.30%
- [--] Month [--] +8,600%
- [--] Months [---] +215%
- [--] Year [---] +131%

### Followers: [-----] [#](/creator/twitter::1350631692755628034/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1350631692755628034/c:line/m:followers.svg)

- [--] Week [-----] +22%
- [--] Months [-----] +276%
- [--] Year [-----] +621%

### CreatorRank: [-------] [#](/creator/twitter::1350631692755628034/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1350631692755628034/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  31% [countries](/list/countries)  21% [stocks](/list/stocks)  19% [technology brands](/list/technology-brands)  8% [cryptocurrencies](/list/cryptocurrencies)  6% [celebrities](/list/celebrities)  4% [travel destinations](/list/travel-destinations)  3% [exchanges](/list/exchanges)  2% [automotive brands](/list/automotive-brands)  2% [currencies](/list/currencies)  1%

**Social topic influence**
[$ibrx](/topic/$ibrx) #3, [saudi arabia](/topic/saudi-arabia) #249, [in the](/topic/in-the) 7%, [market cap](/topic/market-cap) 6%, [investment](/topic/investment) 6%, [$mrk](/topic/$mrk) 5%, [more than](/topic/more-than) 4%, [future](/topic/future) 4%, [middle east](/topic/middle-east) 4%, [at least](/topic/at-least) #634

**Top accounts mentioned or mentioned by**
[@drpatrick](/creator/undefined) [@immunitybio](/creator/undefined) [@alhmd120690](/creator/undefined) [@elonmusk](/creator/undefined) [@sandygl88167783](/creator/undefined) [@salmonstockcar](/creator/undefined) [@greenwichls](/creator/undefined) [@richadcock](/creator/undefined) [@deepvalue69420](/creator/undefined) [@elwalvador](/creator/undefined) [@mannilotrader](/creator/undefined) [@petitnong](/creator/undefined) [@cryptozz9](/creator/undefined) [@truedat999](/creator/undefined) [@saiseiinvesting](/creator/undefined) [@soldbyjashan](/creator/undefined) [@berlinergy](/creator/undefined)

**Top assets mentioned**
[ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Merck & Co., Inc. (MRK)](/topic/$mrk) [IonQ, Inc. (IONQ)](/topic/$ionq) [Opendoor Technologies Inc Common Stock (OPEN)](/topic/$open) [World3 (WAI)](/topic/$wai) [Erayak Power Solution Group Inc. (RAYA)](/topic/$raya) [AgriDex (AGRI)](/topic/$agri) [Rigetti Computing, Inc. Common Stock (RGTI)](/topic/$rgti) [Blend Labs, Inc. (BLND)](/topic/$blnd) [Tesla, Inc. (TSLA)](/topic/tesla) [Greenwich LifeSciences, Inc. (GLSI)](/topic/$glsi) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Advanced Micro Devices (AMD)](/topic/$amd) [Eli Lilly and Company (LLY)](/topic/$lly) [Amazon.com, Inc. (AMZN)](/topic/$amzn) [Rivian Automotive, Inc.  (RIVN)](/topic/$rivn) [Astera Labs, Inc. (ALAB)](/topic/$alab) [Marvell Technology Inc (MRVL)](/topic/$mrvl)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$glsi Greenwich Lifesciences Unrivaled Efficacy: The 0% recurrence rate from previous trials is extraordinary in oncology; Phase [--] is currently validating this trend. Commercial Readiness: The FDA's approval of the commercial manufacturing lot on January [--] [----] clears a major regulatory hurdle paving the way for immediate market entry upon clinical success. @GreenwichLS https://twitter.com/i/web/status/2014608941028970972 https://twitter.com/i/web/status/2014608941028970972"  
[X Link](https://x.com/petitnong_/status/2014608941028970972)  2026-01-23T07:59Z [----] followers, [----] engagements


"$IBRX is undervalued even at $10 per share. Alteogen a Korean company receiving a 2% royalty from $MRK for Keytruda has a market cap of approximately $13.7B. $IBRX is the company that will usher in a new era of 4th-generation cancer immunotherapy as shown in the image. $IBRX is trading on the potential of many indications. If the company can lock in 1-2 more (beyond bladder) with solid data - $20-30 / share if Anktiva/NK supports care in all indications - $50-100. $IBRX is trading on the potential of many indications. If the company can lock in 1-2 more (beyond bladder) with solid data -"  
[X Link](https://x.com/petitnong_/status/2014634281398865994)  2026-01-23T09:40Z [----] followers, 14.3K engagements


"@DrPatrick @ImmunityBio I'm curious about something. Was there ever an official or rumored $30 billion acquisition bid for ImmunityBio from Merck $MRK"  
[X Link](https://x.com/petitnong_/status/2015591257834389612)  2026-01-26T01:02Z [---] followers, [---] engagements


"@DrPatrick @ImmunityBio I have a question. Has ImmunityBio ever received an acquisition offer from $MRK (Merck) for around $30 billion $ibrx"  
[X Link](https://x.com/petitnong_/status/2015597172839120937)  2026-01-26T01:26Z [---] followers, [----] engagements


"Many Big Pharma companies are currently bracing for a massive "patent cliff" as their blockbuster oncology drugs approach expiration. For Merck ( $MRK) the stakes are particularly high; Keytruda accounts for more than half of its total revenue and its [----] patent expiration could fundamentally destabilize the entire company. In addition to Merck Bristol Myers Squibb (BMS $BMY) is facing the expiration of Eliquis and Opdivo in [----] and [----] respectively. To fill the resulting revenue gaps these giants are desperately pursuing aggressive M&A (Mergers and Acquisitions) strategies. Similarly"  
[X Link](https://x.com/petitnong_/status/2015774089521004900)  2026-01-26T13:09Z [---] followers, [----] engagements


"#ImmunityBio aims to turn cancer into a manageable disease through immunotherapy within the next [--] years. We can achieve this by targeting and reducing regulatory T cells (Tregs) around cancer cells. Most importantly 90% of cancer deaths are caused by metastasis. By regulating regulatory T cells in the early stages of cancer to enhance the immune response we can prevent metastasis from occurring. This approach can also be applied to suppress organ transplant rejection. It may take up to [--] years but the era where cancer is treated through immunity will surely come. $ibrx @ImmunityBio"  
[X Link](https://x.com/petitnong_/status/2015940720046309691)  2026-01-27T00:11Z [----] followers, [----] engagements


"Wow. My goal was to hit $0.01B for my retirement fund and Im almost there Please join me in celebrating. Ive done every job imaginable and lived so frugally holding back on everything I wanted to do just to save up. Then thanks to ImmunityBio I finally opened my eyes to investing and things have escalated so quickly. It would have been so much tougher without my friends here on X. I am incredibly grateful to all my X friends who have been on this journey with me. Now I only need $0.009999B more to officially retire. Imagining the day $IBRX hits $100. 🚀"  
[X Link](https://x.com/petitnong_/status/2016068405095542843)  2026-01-27T08:38Z [---] followers, [----] engagements


"The non-small cell lung cancer (NSCLC) market is approximately [--] to [--] times larger than the bladder cancer market. On January [--] [----] ImmunityBio received marketing approval for NSCLC in Saudi Arabia and is currently selling the treatment. ImmunityBios NSCLC treatment has been granted Breakthrough Therapy Designation making it eligible for a significantly expedited review process. Saudi Arabia recognized this potential and issued the worlds first accelerated approval. ANKTIVA is being evaluated as a more advanced technology than Keytruda as it re-triggers immune responses in patients who have"  
[X Link](https://x.com/petitnong_/status/2016124729443418186)  2026-01-27T12:22Z [---] followers, [----] engagements


"$mrno closed at $3.23 per share in the Asian market. With low floating shares if a proper short squeeze occurs it looks like it could become the next $smx Today Id like to take a moment to talk about $MRNO. I have been swing trading this ticker for a while now. Since the majority shareholders own 98.3% of the shares the actual float is only 1.7% meaning there are only about [---] million shares available for trading. Ive been Today Id like to take a moment to talk about $MRNO. I have been swing trading this ticker for a while now. Since the majority shareholders own 98.3% of the shares the"  
[X Link](https://x.com/petitnong_/status/2016433578519974279)  2026-01-28T08:50Z [---] followers, [---] engagements


"Will ImmunityBio $IBRX be a game-changer for Long COVID Dr. Patrick Soon-Shiong presented clinical data on Bioshield. Beyond remission in cancer patients two clinical trials are underway to eliminate persistent virus from the bodies of Long COVID patients. [--]. Bioshield Achievements Confirmed meaningful remission and improved quality of life in cancer patients who had exhausted standard treatment options. [--]. Long COVID Clinical Trials The goal is not just symptom relief but using NK cells to clear the SARS-CoV-2 virus persisting in tissues. (2 trials currently in progress) [--]. Future Timeline"  
[X Link](https://x.com/petitnong_/status/2017746355821941202)  2026-01-31T23:46Z [----] followers, [----] engagements


"ImmunityBio is preparing for the mass production of ANKTIVA. It wont just be Merck $MRK the developer of Keytruda but all other pharmaceutical companies developing oncology treatments that will purchase ANKTIVA for use as a combination therapy. $IBRX @ImmunityBio @DrPatrick $IBRX Anktiva with its amazing results and inspiring life saving testimonials also works great with Keytruda for lung cancer. Keytruda just happens to be the best seller out there. Anktiva- approved U.S. bladder cancer and recently approved in Saudi Arabia for lung cancer https://t.co/QX9pA52lGQ $IBRX Anktiva with its"  
[X Link](https://x.com/petitnong_/status/2017767690572861694)  2026-02-01T01:11Z [----] followers, [----] engagements


"In a previous clinical trial for refractory B-cell lymphoma 100% of the four-patient cohort achieved clinical disease control. By adding ANKTIVA to this regimen we expect to powerfully proliferate and activate immune cells (NK and T-cells) creating a synergy that drives even more potent anti-tumor activity than conventional methods. Notably every patient treated to date has completed their therapy in an outpatient setting without significant immune-related toxicities proving its exceptional safety profile $IBRX @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2018471297806929949"  
[X Link](https://x.com/petitnong_/status/2018471297806929949)  2026-02-02T23:47Z [---] followers, [----] engagements


"$AMD MI325X and MI350X series are generating significant revenue from major cloud customers including Oracle and OpenAI. Capitalizing on Intels struggles AMD has successfully pushed its data center market share up to 30%. In particular the increasing share of the 5th-generation EPYC processors is expected to drive substantial improvements in profitability. The key for the upcoming earnings will be how recent increases in memory prices such as HBM and supply chain bottlenecks have impacted overall margins. Someone purchased $4M worth of OTM Calls on $AMD. AMD reports earnings tomorrow."  
[X Link](https://x.com/petitnong_/status/2018652277356277966)  2026-02-03T11:46Z [---] followers, [---] engagements


"Micron Idaho fab is more than just a factory; it is set to become the central hub for producing leading-edge DRAM and HBM. Based on production efficiency relative to cleanroom size the facility is estimated to have the potential to generate between $8 billion and $12 billion in annual revenue. Considering Microns total revenue in [----] was approximately $37.4 billion this single new fab could account for a massive 25% to 30% of the companys entire revenue $MU #Micron Micron has completed a major structural milestone of our new Idaho fab Built from [-----] tons of American steelnearly the amount"  
[X Link](https://x.com/petitnong_/status/2018823129762861417)  2026-02-03T23:05Z [---] followers, [---] engagements


"On Jan [--] ImmunityBio secured Saudi approval for its bladder and lung cancer treatments paving the way for a Middle East-wide launch. This is a game-changing 'free pass' that enables market expansion across the region without further clinical approval $ibrx @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2019308984566677974 https://twitter.com/i/web/status/2019308984566677974"  
[X Link](https://x.com/petitnong_/status/2019308984566677974)  2026-02-05T07:15Z [----] followers, [----] engagements


"While other companies may have higher revenue from non-oncology sectors ImmunityBios market cap remains absurdly undervalued when considering its future potential. Solid tumors account for 90% of all cancer patients and 40% of them experience lymphopenia during treatment. Once the approval for treating lymphopenia is secured we can expect a significant surge in the stock price. $ibrx @DrPatrick https://twitter.com/i/web/status/2019310152772653490 https://twitter.com/i/web/status/2019310152772653490"  
[X Link](https://x.com/petitnong_/status/2019310152772653490)  2026-02-05T07:20Z [----] followers, [---] engagements


"It is true. ImmunityBio plans to establish a regional office in Saudi Arabia to expand the supply of its treatments across the Middle East and North Africa (MENA) region. $ibrx @DrPatrick @ImmunityBio $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants the treatment available. Correct me if I am wrong. $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants"  
[X Link](https://x.com/petitnong_/status/2019327926135820751)  2026-02-05T08:31Z [---] followers, [--] engagements


"It is true. ImmunityBio plans to establish a regional office in Saudi Arabia to expand the supply of its treatments across the Middle East and North Africa (MENA) region. $ibrx @DrPatrick @ImmunityBio $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants the treatment available. Correct me if I am wrong. $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants"  
[X Link](https://x.com/petitnong_/status/2019367815816626687)  2026-02-05T11:09Z [----] followers, [---] engagements


"It is true. ImmunityBio plans to establish a regional office in Saudi Arabia to expand the supply of its treatments across the Middle East and North Africa (MENA) region. $ibrx @DrPatrick @ImmunityBio $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants the treatment available. Correct me if I am wrong. $IBRX Not sure if I heard @DrPatrick correctly today but I thought he said-Saudi Arabia wants #ANKTIVA for all tumor types and that Qatar spoke with him today and also wants"  
[X Link](https://x.com/petitnong_/status/2019367815837544772)  2026-02-05T11:09Z [----] followers, [----] engagements


"With the recent approval in Saudi Arabia ImmunityBio can now launch sales directly across the Middle East by leveraging local regulatory frameworks without the need for additional clinical trials. It is now only a matter of time before full commercialization begins and more positive catalysts are expected to follow. $ibrx @ImmunityBio @DrPatrick $IBRX @DrPatrick announced that Saudi Arabia is interested in expanding ANKTIVA & BioShield cure to many other type of cancers while UAE is now considering it as well. He hopes current US Admin wont waste more time and follow suit."  
[X Link](https://x.com/petitnong_/status/2019418127172530562)  2026-02-05T14:29Z [----] followers, [---] engagements


"@DrPatrick aims to establish Saudi Arabia as a regional hub for medical biotechnology with the goal of expanding ImmunityBios solutions not only across the Middle East but globally. He seeks to achieve cross-border investment and technology transfer opportunities throughout the entire process from R&D to manufacturing and clinical deployment. By connecting advanced American manufacturing robotics and AI technologies with Saudi healthcare institutions he intends to create validated clinical impact at scale. $ibrx @ImmunityBio USA Saudi Biotech Alliance https://t.co/jFSlk3gudV USA Saudi Biotech"  
[X Link](https://x.com/petitnong_/status/2020267995214528736)  2026-02-07T22:46Z [----] followers, [---] engagements


"@ImmunityBio boasts an "Avengers-level" team of leaders. Starting with CEO @richadcock the team includes Leonard S. Sender M.D. who leads clinical trials in the fields of hematologic malignancies and cell therapy. Sandeep Reddy M.D. is responsible for clinical and diagnostic strategies in solid tumors including bladder lung and brain cancers. Enrique Dilon Ph.D. takes charge of complex biopharmaceutical manufacturing and technological innovation at ImmunityBio. Charles G. Garlisi Ph.D. plays a pivotal role in new drug approvals overseeing FDA Biologics License Application (BLA) submissions"  
[X Link](https://x.com/petitnong_/status/2020273709773385937)  2026-02-07T23:09Z [----] followers, [---] engagements


"@Alhmd120690 The official news regarding the approval was released on January 16"  
[X Link](https://x.com/petitnong_/status/2020304318981943803)  2026-02-08T01:10Z [----] followers, [---] engagements


"Next Week's Schedule Monday: FOMC Chairman's Speech Tuesday: Fed's Liquidity Injection ($8.3 Billion) Wednesday: Federal Budget Balance Thursday: Federal Reserve Balance Sheet Friday: U.S. Economic Survey Saturday: China's Money Supply (M2) Data Sunday: Japan's GDP"  
[X Link](https://x.com/petitnong_/status/2020476365976285270)  2026-02-08T12:34Z [----] followers, [---] engagements


"If [----] was the year of revenue generation through the U.S. launch of ANKTIVA [----] will be the year of explosive revenue growth triggered by its approval in Europe. Even now sales volume has been steadily increasing in the United States and I believe that a growth of at least [--] to [--] times compared to the previous year is well within reach even by conservative estimates. $IBRX @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2020736112252399994 https://twitter.com/i/web/status/2020736112252399994"  
[X Link](https://x.com/petitnong_/status/2020736112252399994)  2026-02-09T05:46Z [----] followers, [---] engagements


"ImmunityBio $IBRX Target Valuation & Market Cap Projections Current Valuation (Intrinsic Fair Value) Estimated Market Cap: $18B $25B Revenue Explosion: FY2025 net product revenue grew by 700% year-over-year to approximately $113M. This performance demonstrates the companys successful transition from clinical research to a fully-realized commercial stage. J-Code Impact: The establishment of a permanent J-Code in the U.S. has led to a surge in prescriptions through streamlined reimbursement. Global expansion is also underway with regulatory milestones in Saudi Arabia and the U.K. Oncology"  
[X Link](https://x.com/petitnong_/status/2016846186251243976)  2026-01-29T12:09Z [----] followers, [----] engagements


"Saudi Arabia is highly likely to invest at least $1.5 billion to $2.2 billion solely through providing plant sites and supporting construction costs for #ImmunityBio In addition the Saudi Public Investment Fund (PIF) has a strong track record of directly acquiring stakes in promising partner companies. If PIF decides to pursue a direct equity investment in ImmunityBio a capital injection ranging from $0.8 billion to $1.5 billion seems plausible based on previous cases in other strategic industries. Even more significant than an immediate cash injection is the potential for a "bulk purchase""  
[X Link](https://x.com/petitnong_/status/2021585969502433414)  2026-02-11T14:03Z [----] followers, [----] engagements


"Its surprising that @DrPatrick hasnt tweeted for two days straight. Hes likely away because hes focused on the European marketing authorization for the bladder cancer treatment which is expected this Friday $ibrx @ImmunityBio"  
[X Link](https://x.com/petitnong_/status/2021813433587626079)  2026-02-12T05:07Z [----] followers, [---] engagements


"NSCLC patients facing progression after first-line therapy often have a median survival of less than [--] months with few effective options remaining. Current NCCN guidelines even advise against re-using the same class of immunotherapy after failure. ImmunityBio is breaking this barrier with a global Phase [--] trial combining ANKTIVA with checkpoint inhibitors for treatment-resistant patients. The results are groundbreaking: patients who recovered their immune function through ANKTIVA achieved a median survival of [----] months more than doubling the [--] month survival rate of the current standard"  
[X Link](https://x.com/petitnong_/status/2017939914768388229)  2026-02-01T12:35Z [----] followers, [---] engagements


"I have launched an ImmunityBio community to gather and organize information about $IBRX Everyone is welcome to join"  
[X Link](https://x.com/petitnong_/status/2019304215169101839)  2026-02-05T06:56Z [----] followers, [----] engagements


"The man who will change the history of the bio market. @DrPatrick $ibrx What a beautiful moment caught on camera in Riyadh. A brilliant scientist from Harvard meeting for the first time with an Ex UCLA surgeon discussing how we together solve humanitys biggest health challenges brought together by His Excellency Bandar working together not as https://t.co/3UJGKl1VOs What a beautiful moment caught on camera in Riyadh. A brilliant scientist from Harvard meeting for the first time with an Ex UCLA surgeon discussing how we together solve humanitys biggest health challenges brought together by His"  
[X Link](https://x.com/petitnong_/status/2019523558347796593)  2026-02-05T21:28Z [----] followers, [----] engagements


"Patents for the combination of ANKTIVA with BCG as well as the combination of ANKTIVA with checkpoint inhibitors are protected until at least [----]. The company holds more than [---] granted patents worldwide and its biologics exclusivity extends until [----]. $ibrx @DrPatrick @ImmunityBio https://twitter.com/i/web/status/2020271497747788049 https://twitter.com/i/web/status/2020271497747788049"  
[X Link](https://x.com/petitnong_/status/2020271497747788049)  2026-02-07T23:00Z [----] followers, [----] engagements


"The fact that a Big Pharma company like $LLY acquired Orna which shares the same technology as ImmunityBio proves that the value of circular RNA technology has been officially recognized. As a shareholder I do not want ImmunityBio to be sold. Since they have come this far by independently developing the technology of Anktiva I hope to see them truly shine on their own $ibrx @DrPatrick @ImmunityBio Big Pharma is finally waking up that cell therapies are the future of immunotherapy [---] https://t.co/3PuzztBIUZ Big Pharma is finally waking up that cell therapies are the future of immunotherapy"  
[X Link](https://x.com/petitnong_/status/2020954789375520799)  2026-02-09T20:15Z [----] followers, [----] engagements


"1. Unveiling Next-Generation Therapies We are sharing the combination therapy of ANKTIVA and NK cell therapy with medical leaders in Saudi Arabia and accelerating preparations for its official launch. This marks the beginning of Immunotherapy [---]. [--]. Expansion of the Bioshield Based on decades of clinical data we plan to significantly expand indications to various solid tumors including breast lung prostate brain (GBM) and colon cancer. [--]. Validation of the NantCancer Vaccine We will officially present the efficacy of our patented cancer vaccine validated through cumulative clinical results"  
[X Link](https://x.com/petitnong_/status/2020958268366127516)  2026-02-09T20:29Z [----] followers, [---] engagements


"The summit is scheduled to be held in Riyadh the capital of Saudi Arabia from February 26th to 28th [----]. Building on previous discussions this event will serve as an official platform to formalize the practical launch of the ANKTIVA and NK cell therapy combination in Saudi Arabia and its global expansion. $ibrx @ImmunityBio @DrPatrick #immunitybio The 2nd USA: Saudi Biotech Alliance summit to be held this month in Rhiyadh - this time a sharing of all the combinations of Anktiva and NK cell therapy with oncology thought leaders and leadership in Saudi and setting the launch of Anktiva with"  
[X Link](https://x.com/petitnong_/status/2020965925743407558)  2026-02-09T20:59Z [----] followers, [---] engagements


"Saudi Arabia is heavily promoting the biotech industry for the post-oil era and ImmunityBios ANKTIVA and NK cell technology have been selected to be at the center of this movement. The main agenda of this summit is the official launch of the ANKTIVA and NK cell therapy combination in Saudi Arabia and its subsequent global expansion. Dr. Soon-Shiong plans to unveil decades of research results to Saudi medical leaders all at once with the goal of establishing Saudi Arabia as the world's first hub for conquering cancer. In this sense the summit is truly a solo stage for ImmunityBio. $ibrx"  
[X Link](https://x.com/petitnong_/status/2020966699886051765)  2026-02-09T21:03Z [----] followers, [----] engagements


"The approval for the commercial launch of the bladder cancer treatment is expected to be announced within this week. Revenue has already surged by 700% in just one year from U.S. sales alone. While the U.S. market continues to expand how much more will the revenue grow once sales begin in the European and Middle Eastern markets $ibrx @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2021024927479103979 https://twitter.com/i/web/status/2021024927479103979"  
[X Link](https://x.com/petitnong_/status/2021024927479103979)  2026-02-10T00:54Z [----] followers, [---] engagements


"Amazon Q4 [----] 13F Filings $AMZN No Change (Holdings Maintained) $RIVN $ALAB $MRVL $NAUT New Positions (New Additions) $IONQ $BETA Exited Positions (Sold All Shares) $OWLT $SMRT $VITL"  
[X Link](https://x.com/petitnong_/status/2021348275593650259)  2026-02-10T22:19Z [----] followers, [---] engagements


"I have been a shareholder of $IONQ since its days as a SPAC before it officially went public. Recently as quantum computing companies have started gaining significant attention many obscure companies are claiming to be in the quantum business and quickly showing off their "technological prowess." While the quantum cryptography market is relatively easy to enter and penetrate quickly the quantum hardware market is a completely different storyit's incredibly challenging. I wont name any specific "junk stocks" but please be cautious with your investments."  
[X Link](https://x.com/petitnong_/status/2021532484291469727)  2026-02-11T10:31Z [----] followers, [---] engagements


"Please keep a close eye on $IBRX this Friday. The European EMA's CHMP meeting is taking place from February 9th to the 12th. Typically the CHMP releases the full list of 'Positive Opinions' (recommendations for approval) on the Friday immediately following their four-day session. @DrPatrick @ImmunityBio https://twitter.com/i/web/status/2021578270584750332 https://twitter.com/i/web/status/2021578270584750332"  
[X Link](https://x.com/petitnong_/status/2021578270584750332)  2026-02-11T13:33Z [----] followers, [----] engagements


"#Alphabet Q4 [----] Earnings Results Key Financials Revenue: $113.83 billion up 18% YoY Earnings Per Share (EPS): $2.82 up 31% YoY Operating Income: $35.93 billion up 16% YoY [----] Capital Expenditures (CapEx) Plan: $175 billion $185 billion Segment Performance Google Cloud Revenue: $17.66 billion up 48% YoY Google Services Revenue: $95.86 billion up 14% YoY Google Advertising Revenue: $82.28 billion up 14% YoY Google Search & Others Revenue: $63.07 billion up 17% YoY YouTube Ads Revenue: $11.38 billion up 9% YoY Operating & Financial Metrics Revenue excluding TAC: $97.23 billion up 19% YoY"  
[X Link](https://x.com/petitnong_/status/2019192524527825258)  2026-02-04T23:33Z [----] followers, [---] engagements


"This is the $IBRX community I am currently managing. By joining you can gain access to a wide range of in-depth information and the latest updates related to ImmunityBio. @ImmunityBio @DrPatrick"  
[X Link](https://x.com/petitnong_/status/2020967803562623056)  2026-02-09T21:07Z [----] followers, [----] engagements


"$ibrx Key News and Announcements Expected in February [--]. Expected Approval for Bladder Cancer (NMIBC) Sales in Europe and the UK - Recorded 700% revenue growth from U.S. sales alone. [--]. The 2nd USA-Saudi Biotech Alliance Summit (Feb [--] Feb 28) - Plans to officialize the launch of the ANKTIVA and NK cell therapy combination in Saudi Arabia and announce specific plans to establish Saudi Arabia as the world's first hub for conquering cancer. - Possibility of additional inflows of Middle Eastern capital or securing contracts for the construction of local production facilities. [--]. Sharing of"  
[X Link](https://x.com/petitnong_/status/2021160342240493730)  2026-02-10T09:52Z [----] followers, [----] engagements


"Nice $ibrx $IBRX Goldman Sachs Group ImmunityBio Seventh Largest Institutional Holder Increases Its Stake By 5mil Shares In 4Q25 ie +439% Reaching Up 6.2mil Shares Overall. https://t.co/6FCGadThIH $IBRX Goldman Sachs Group ImmunityBio Seventh Largest Institutional Holder Increases Its Stake By 5mil Shares In 4Q25 ie +439% Reaching Up 6.2mil Shares Overall. https://t.co/6FCGadThIH"  
[X Link](https://x.com/petitnong_/status/2021581743845728588)  2026-02-11T13:47Z [----] followers, [----] engagements


"I hope there are no casualties #China BREAKING: A massive sinkhole suddenly opened in Shanghai China swallowing a large section of roadway. https://t.co/90RrKh6aJf BREAKING: A massive sinkhole suddenly opened in Shanghai China swallowing a large section of roadway. https://t.co/90RrKh6aJf"  
[X Link](https://x.com/petitnong_/status/2021889736869392446)  2026-02-12T10:10Z [----] followers, [---] engagements


"$achv Its confirmed that companies must notify internally by Day [--] but their public PR can drop anytime afterranging from Day [--] to Day 70+ (thats straight GPT logic). Anyway since the 60-day mark is reached expect ACHV-related news to drop anytime before the 74-day letter deadline (Sep 8). Reminds me of IXHL: they said clinical results were coming in July but the stock pumped just on anticipation no PR no actual news. Also found on Stocktwits: ACHV has submitted to the FDAs new CNPV pilot program. This was mentioned in the last earnings call when a Raymond James analysta firm with a $20"  
[X Link](https://x.com/skirrelonmusk/status/1960693626998284639)  2025-08-27T13:19Z [---] followers, [----] engagements


"$achv Once a company submits its NDA the FDA must respond with either Acceptance or RTF (Refuse to File) on Day 60no exceptions. For ACHV the NDA went in on June [--] so the key date is August [--] (with July having [--] days). If the FDA hits ACHV with an RTF its game over. But after a deficiency letter last year ACHV already ran extra trials and got the green light to resubmit so the odds of an RTF here are very low. For comparison Tonix filed its NDA on Oct [--] [----] and got acceptance on Dec [--]. That single news release sent the stock from $22 (post reverse split) to $130. Not saying to expect"  
[X Link](https://x.com/skirrelonmusk/status/1960694382790943035)  2025-08-27T13:22Z [---] followers, [---] engagements


"After $WAI lets jump into $RAYA loading up for that short squeeze run $TNFA $BINI $NBY $AZTR $PTNM $BTAI $IXHL $RAYA $OPEN $MODV $AGRI $FLNT $DEVS $RGTI $DSS"  
[X Link](https://x.com/skirrelonmusk/status/1960704047964676594)  2025-08-27T14:00Z [---] followers, [---] engagements


"Following $WAI were moving into $RAYA stacking up shares ahead of the short squeeze. $TNFA $BINI $NBY $AZTR $PTNM $BTAI $IXHL $RAYA $OPEN $MODV $AGRI $FLNT $DEVS $RGTI $DSS"  
[X Link](https://x.com/skirrelonmusk/status/1960704459249500378)  2025-08-27T14:02Z [---] followers, [---] engagements


"$PTNM Hong Kong theme today $SKBL just finishing off a nice C&H breakout now $PTNM is setting up players will move over and send it"  
[X Link](https://x.com/skirrelonmusk/status/1960730900506784210)  2025-08-27T15:47Z [---] followers, [---] engagements


"$PTNM damn boi he thiccc $RR $TLRY"  
[X Link](https://x.com/skirrelonmusk/status/1960731937213178329)  2025-08-27T15:51Z [---] followers, [---] engagements


"$ATNF ran up because Peter Thiel filed a stake disclosure lol. $CRE is just insiders keeping the same holdings and disclosing them nothing new. Dumbass. Remember how $ATNF ran 600% recently $CRE huge 13D out today 💵✍✅ Remember how $ATNF ran 600% recently $CRE huge 13D out today 💵✍✅"  
[X Link](https://x.com/skirrelonmusk/status/1960780405621317860)  2025-08-27T19:04Z [---] followers, [---] engagements


"$jem According to some articles the SEC supposedly launched a regulatory investigation on September [--]. However there is no such filing related to the company on the SEC websitethere is no September [--] document at all. The articles also provide no documents no photos and no clear evidencejust words written by a reporter. This makes it highly likely that its simply a false rumor. On the SEC website the last filing related to [---] Cayman was on August [--]. Today is September [--] and if there had really been an investigation on September [--] theres no reason such a document wouldnt have been uploaded by"  
[X Link](https://x.com/skirrelonmusk/status/1963978063957377083)  2025-09-05T14:50Z [---] followers, [---] engagements


"Next real estate play to watch after $open Opendoor: Beeline Holdings (NASDAQ: $BLND) Business Segments Digital Mortgage & Title (Loan Origination): Beeline isnt a bank but an AI-driven fintech automating the mortgage process. Revenue comes mainly from mortgage and title fees. Q2 [----] revenue of $1.7M was largely from this segment. SaaS / AI Platform & Investments: Beyond lending Beeline invests in and develops AI solutions. It owns 47.6% of MagicBlocks an AI customer-engagement platform and runs Beeline Labs for SaaS/data subscriptions. Key Highlights from the Shareholder Letter 1.Debt-Free"  
[X Link](https://x.com/skirrelonmusk/status/1964114077736714517)  2025-09-05T23:51Z [---] followers, [---] engagements


"Beeline Holdings (NASDAQ: $BLND) Next Real Estate Fintech Runner Debt-free uplisted to NASDAQ and now rolling out BeelineEquity (tokenized home equity) with [----] deals lined up. Already cash-flow positive trajectory by early [----] Q2 beat expectations and AI sales agent Bob booked $170K+ revenue. Stake in MagicBlocks (47.6%) adds SaaS/AI upside. With the CEO personally $16M invested $BLND is positioning like $OPEN didlean AI-driven and built for scale"  
[X Link](https://x.com/skirrelonmusk/status/1964960250366132703)  2025-09-08T07:53Z [---] followers, [---] engagements


"$IBRX This one has a massive 10x upside potential within the next [--] years. They hold the 4th-gen immunotherapy tech thats set to become the next Keytruda. The technology is already proving itself and once the global rollout hits full scale we're looking at a completely different ball game. Don't wait until everyone else is talking about it. @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2014161458817568863 https://twitter.com/i/web/status/2014161458817568863"  
[X Link](https://x.com/petitnong_/status/2014161458817568863)  2026-01-22T02:21Z [---] followers, [--] engagements


"BlackRock is buying up the sleeping $IONQ and increasing their stake $IONQ Blackrock reports that it increases stake in Ionq by [--------] shares now owns [--------] shares (or 7.8%) of Ionq. https://t.co/MTqg2pPQdw $IONQ Blackrock reports that it increases stake in Ionq by [--------] shares now owns [--------] shares (or 7.8%) of Ionq. https://t.co/MTqg2pPQdw"  
[X Link](https://x.com/petitnong_/status/2014462144738451522)  2026-01-22T22:16Z [---] followers, [---] engagements


"$IBRX ImmunityBio is Set to Disrupt the Bio Industry in [--------] ImmunityBios Anktiva is the leading stock among fourth-generation cancer therapy companies and is poised to shift the paradigm of the biotech market. [--]. 2026: EU market launch for Bladder Cancer. [--]. Late 2026: U.S. market launch for Non-Small Cell Lung Cancer (NSCLC). [--]. Q3 2026: Market launch for Papillary Bladder Cancer. [--]. 20262027: Market launch for various Solid Tumors. While other companies spend a year weighing Phase [--] and [--] trials ImmunityBio holds four distinct catalysts for market authorization and commercialization."  
[X Link](https://x.com/petitnong_/status/2014509626843410794)  2026-01-23T01:24Z [---] followers, [----] engagements


"Reasons for $BNAI Surge [--]. Brand Engagement Network (BEN) has secured a contract with a leading global advertising agency to provide a custom AI engagement solution for a prescription drug campaign of one of the world's top [--] pharmaceutical companies. [--]. The stock is experiencing a high short interest of approximately 40% which combined with a low public float has created significant upward pressure. https://twitter.com/i/web/status/2014818110474486079 https://twitter.com/i/web/status/2014818110474486079"  
[X Link](https://x.com/petitnong_/status/2014818110474486079)  2026-01-23T21:50Z [---] followers, [---] engagements


"$IBRX Shorts on the Brink of Collapse Check out the $IBRX short data right now. This is serious. Its not just about the stock price going up; the shorts have literally run out of shares to borrow. There are zero shares available for shorting. The borrow fee which was only in the 3% range back on January 19th has skyrocketed to 75.52%. Those who shorted this are going to see their accounts melt away just trying to cover the interest every time they wake up. Reports already show that short sellers have lost over $500 million (650 billion KRW) so far in January. If even one more piece of good"  
[X Link](https://x.com/petitnong_/status/2014826352554475717)  2026-01-23T22:23Z [---] followers, [----] engagements


"The fact that the Median Overall Survival (mOS) has not yet been reached means that the survival rate is so high (due to fewer deaths than expected) that a definitive evaluation cannot be made yet. "Median" refers to the specific point in time when exactly 50% of the patients in a study have passed away. As of the latest update [--] out of [--] enrolled patients are still alive meaning only [--] deaths have occurred. Rather than just saying "mOS has not been reached" it would be more accurate to say "The drug's efficacy is so outstanding that we haven't even been able to fully evaluate its upper"  
[X Link](https://x.com/petitnong_/status/2014830489555894516)  2026-01-23T22:39Z [---] followers, [----] engagements


"AST SpaceMobile (ASTS) vs. Starlink (SpaceX) AST SpaceMobile ($ASTS) [--]. Direct connection between satellites and mobile phones [--]. No smartphone modification required [--]. Large satellite size per unit [--]. Collaboration with existing mobile network operators [--]. Use of terrestrial mobile communication bands [--]. Cellular signals can be received in the middle of mountains or oceans using only a smartphone with no additional equipment required. Starlink (SpaceX) [--]. Dedicated antenna required [--]. Receiver terminal essential [--]. Small satellite size per unit [--]. Independent satellite internet service 5."  
[X Link](https://x.com/petitnong_/status/2015235487250964898)  2026-01-25T01:29Z [---] followers, [---] engagements


"@Deepvalue69420 @elwalvador ImmunityBio's therapeutic for non-small cell lung cancer (NSCLC) has been designated as a Breakthrough Therapy by the FDA and has recently received the world's first accelerated approval in Saudi Arabia"  
[X Link](https://x.com/petitnong_/status/2015334422611149190)  2026-01-25T08:02Z [---] followers, [---] engagements


"Introduction to ImmunityBios Non-Small Cell Lung Cancer (NSCLC) Therapeutic ImmunityBios therapeutic for NSCLC received marketing approval in Saudi Arabia on January [--] [----]. In the United States it has been designated as a Breakthrough Therapy by the FDA with accelerated approval (marketing authorization) anticipated by the end of [----]. With approximately [---] million new cases occurring globally each year this treatment holds the title of being the worlds first to utilize a subcutaneous (SC) injection method for this indication. Why ImmunityBios Treatment is Gaining Attention The primary"  
[X Link](https://x.com/petitnong_/status/2015346897612165614)  2026-01-25T08:51Z [---] followers, [----] engagements


"ImmunityBio Bladder Cancer Treatment Interestingly ImmunityBios bladder cancer treatment actually faced an initial FDA rejection back in [----]. The drugs efficacy was never the issue; rather it was due to deficiencies found at a third-party contract manufacturing facility. After resolving these manufacturing hurdles the company finally secured FDA approval in [----]. While the company aimed to accelerate clinical trials for other indications like lung and pancreatic cancer it faced significant delays. According to market rumors these setbacks were tied to pushback from "Big Pharma" and political"  
[X Link](https://x.com/petitnong_/status/2015373483367448674)  2026-01-25T10:37Z [---] followers, [----] engagements


"Do you really earn [---] billion won per minute @elonmusk MrBeast  [---] ( [--] ) . Elon Musk  [--]. https://t.co/dLBmNj2DRv MrBeast  [---] ( [--] ) . Elon Musk  [--]. https://t.co/dLBmNj2DRv"  
[X Link](https://x.com/petitnong_/status/2015669415380217973)  2026-01-26T06:13Z [---] followers, [---] engagements


"@mannilotrader This is my original content and data. Im curious why you used it without any credit or citation. I hold the full copyright to this material and I expect an explanation for this unauthorized use"  
[X Link](https://x.com/petitnong_/status/2016367716668735821)  2026-01-28T04:28Z [---] followers, [--] engagements


"I will explain the reasons for the increase in the stock price of $rbt. [--]. Once performance I expected to turn a profit in the second half of this year but if I do well it seems possible in the third quarter. -Attempting to turn to the black very steeply"  
[X Link](https://x.com/petitnong_/status/1681181390044553216)  2023-07-18T05:57Z [---] followers, [---] engagements


"$IBRX This one has a massive 10x upside potential within the next [--] years. They hold the 4th-gen immunotherapy tech thats set to become the next Keytruda. The technology is already proving itself and once the global rollout hits full scale we're looking at a completely different ball game. Don't wait until everyone else is talking about it. @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2014166068852568459 https://twitter.com/i/web/status/2014166068852568459"  
[X Link](https://x.com/petitnong_/status/2014166068852568459)  2026-01-22T02:39Z [---] followers, 21.8K engagements


"NSCLC (Non-Small Cell Lung Cancer) is the biggest oncology market making up 80%+ of lung cancers. Clinical trials passed in Saudi Arabia but market cap is still low. A promising 4th-gen anticancer therapy $ibrx $IBRX This one has a massive 10x upside potential within the next [--] years. They hold the 4th-gen immunotherapy tech thats set to become the next Keytruda. The technology is already proving itself and once the global rollout hits full scale we're looking at a completely https://t.co/gYDqp0Ksqk $IBRX This one has a massive 10x upside potential within the next [--] years. They hold the"  
[X Link](https://x.com/petitnong_/status/2014205431334523190)  2026-01-22T05:16Z [---] followers, [----] engagements


"1. Hope for Pancreatic Cancer: Proven significant survival benefits in 3rd to 6th-line metastatic pancreatic cancer where treatment options were previously almost nonexistent. [--]. The First LSA: Demonstrating ANKTIVA's value as the world's first lymphocyte-stimulating agent (LSA). [--]. The Data: A 54% reduction in the risk of death (HR 0.46) upon lymphocyte recovery with median overall survival exceeding [--] months. The fact that the hazard ratio (HR) for death dropped to [----] among pancreatic cancer patients whose lymphocyte counts were reversed is an extraordinary figure. Given that the"  
[X Link](https://x.com/petitnong_/status/2014503601868308974)  2026-01-23T01:01Z [---] followers, [----] engagements


"ImmunityBio currently operates a massive [------] sq ft (approx. [-----] pyeong) automated manufacturing facility for ANKTIVA fully equipped with AI-driven robotics. An FDA announcement regarding the approval of this automation is expected around April or May of this year. Additionally a drug substance production facility spanning [------] sq ft (approx. [----] pyeong) in California is scheduled for completion within the next [--] to [--] months. This infrastructure expansion will serve as a critical foundation ensuring not only the commercial supply of ANKTIVA-based cancer therapies but also securing"  
[X Link](https://x.com/petitnong_/status/2015078795167031622)  2026-01-24T15:06Z [---] followers, 12.4K engagements


"ANKTIVA + CAR-NK = Absolute Game Changer What is CAR-NK It is a cutting-edge therapy where immune cells are extracted from the body genetically engineered for enhanced performance and re-injected. These modified cells circulate throughout the body actively hunting down and destroying cancer cells while self-proliferating to provide continuous protection against recurrence. Glioblastoma (GBM): The Most Lethal Brain Cancer Glioblastoma is the most aggressive form of brain tumor. Brain tumors are classified from Grade [--] to [--] and Glioblastoma is the most dreaded Grade [--] malignant tumor. Until now"  
[X Link](https://x.com/petitnong_/status/2015225107514601617)  2026-01-25T00:48Z [---] followers, 11.6K engagements


"To be honest I believe even $50 is an undervaluation. $IBRX is not just 3rd-generation cancer therapy; it represents 3.5-generation technology. For a company that is rewriting history a target price of $20 per share is absurd. These analysts simply haven't done enough homework on biotechnology. $ibrx $IBRX WEEKEND REALITY CHECK: If you are panicked by the Friday flush to $6.60 zoom out and look at what the pros are doing. We just pulled the updated Analyst Ratings sheet and the consensus is 100% BULLISH. The "Fresh" Ratings (Last [--] Hours): 1- D. Boral Capital (Jason https://t.co/JGLLrMV3kC"  
[X Link](https://x.com/petitnong_/status/2015393893643411674)  2026-01-25T11:58Z [---] followers, 10.9K engagements


"ImmunityBios bladder cancer treatment initially faced an FDA rejection in [----]. The drugs efficacy was never the problem; the rejection was solely due to deficiencies at a third-party contract manufacturing facility. After resolving these manufacturing issues the company finally secured FDA approval in [----]. While there was a strong push to accelerate clinical trials for other indications such as lung and pancreatic cancer the process was hit with significant delays. It has been widely discussed that these setbacks were tied to "Big Pharma" pushback and political friction. Dr. Patrick"  
[X Link](https://x.com/petitnong_/status/2015555957842157772)  2026-01-25T22:42Z [---] followers, [----] engagements


"I compared the market cap of ImmunityBio with other Big Pharma companies that hold leading cancer treatment technologies. Please keep in mind that these large-cap companies also have diverse portfolios in other bio and pharmaceutical sectors. Currently ImmunityBios (IBRX) market cap is only $6.34B. Considering its future potential I believe there is still an upside of at least 20x from the current level. The reasons are simple [--]. Its efficacy is overwhelmingly superior to existing treatments. [--]. We are on the verge of receiving FDA approval for an AI-automated production facility for oncology"  
[X Link](https://x.com/petitnong_/status/2015724057342439820)  2026-01-26T09:50Z [---] followers, [----] engagements


"ImmunityBio Key Catalysts for Q1 [----] Bladder Cancer [--]. Sales Launch in Saudi Arabia: Following the recent SFDA approval ANKTIVA is expected to generate its first international revenue from BCG-unresponsive NMIBC (CIS) patients in Saudi Arabia this quarter. [--]. Indication Expansion in the U.S.: ImmunityBio is advancing its supplemental Biologics License Application (sBLA) for Papillary NMIBC. Following a positive Type B meeting with the FDA in January a resubmission is planned within Q1 to secure approval for high-grade papillary-only patients. [--]. Interim Analysis for First-Line (BCG-Nave)"  
[X Link](https://x.com/petitnong_/status/2015769110941220973)  2026-01-26T12:49Z [---] followers, [----] engagements


"My price target for ImmunityBio $IBRX is $50. I believe my investment acumen surpasses that of most Wall Street analysts. They often set price targets based on current market trends without providing substantive fundamental justification. I doubt there is an analyst out there who understands the intricacies of ImmunityBio better than I do @ImmunityBio @DrPatrick $IBRX Price Targets: $24 - D. Boral (Jason Kolbert) $10 - HC Wainwright (recent raise) $9 - Jefferies Average Target: $11.40 Upside average target: 7680%. Upside on highest target $24: 272%. https://t.co/uTPGnrSGDg $IBRX Price"  
[X Link](https://x.com/petitnong_/status/2016065466587099364)  2026-01-27T08:27Z [---] followers, 13.6K engagements


"I am living proof of the power of ANKTIVA it is the very treatment that saved my life. I believe ANKTIVA is set to rewrite the history of cancer treatment globally. Big Pharma is rightfully intimidated by ImmunityBios growth. Why Because ANKTIVA is not only highly effective in combination with Keytruda but it also shows incredible potential as a monotherapy for patients who have failed Keytruda treatment across various cancer types. Once the AI-automated production lines are fully operational the cost of this therapy could drop to one-tenth of current cancer treatments. ANKTIVA essentially"  
[X Link](https://x.com/petitnong_/status/2016066756666917080)  2026-01-27T08:32Z [---] followers, 15.9K engagements


"$IBRX announced a revenue of $31.8 million for Q3 [----] and is projected to reach approximately $38.3 million in Q4 [----]. This represents a staggering 431% growth compared to the same period last year. ImmunityBio's total revenue for [----] is estimated at around $113 million which is a near 700% increase from the $15 million recorded in [----]. In terms of ANKTIVA's sales volume it has skyrocketed by 750% year-over-year aggressively capturing market share as a leading treatment for bladder cancer. @DrPatrick @ImmunityBio https://twitter.com/i/web/status/2016121000010907958"  
[X Link](https://x.com/petitnong_/status/2016121000010907958)  2026-01-27T12:07Z [---] followers, [----] engagements


"Dear Elon Musk (@elonmusk) I have one small request for you. When sharing my thoughts on X I want to use images that perfectly match and enhance the clarity of my content. Could you please update the platform to allow attaching images within the body of a post (inline images) It would make storytelling on X so much more powerful. I would truly appreciate your consideration #X #Update #FeatureRequest https://twitter.com/i/web/status/2016133276625469628 https://twitter.com/i/web/status/2016133276625469628"  
[X Link](https://x.com/petitnong_/status/2016133276625469628)  2026-01-27T12:56Z [---] followers, [---] engagements


"Why $MRNO is the next $SMX (Short Squeeze Potential) [--]. Sky-high Short Borrow Fee:The annual short borrow fee for $MRNO is currently sitting at approximately 325%. [--]. Zero Shares Available to Borrow:According to data from Fintel and major prime brokerages the number of shares available to borrow is effectively zero. The supply has completely dried up. [--]. Extreme Daily Interest Burden:Assuming a 300% annual interest rate short sellers are forced to pay over 0.8% in interest every single day just to maintain their positions. This creates massive bleeding for anyone betting against the stock. 4."  
[X Link](https://x.com/petitnong_/status/2016367342994014259)  2026-01-28T04:26Z [---] followers, [---] engagements


"This is my original content and data. Im curious why you used it without any credit or citation. I hold the full copyright to this material and I expect an explanation for this unauthorized use. $IBRX is still very cheap thanks to mentally deranged shorts. Don't question them just buy and HODL. $IBRX will pass $50 in FOMO This is a +$100 billion capitalization stock https://t.co/fAJKfCLGad $IBRX is still very cheap thanks to mentally deranged shorts. Don't question them just buy and HODL. $IBRX will pass $50 in FOMO This is a +$100 billion capitalization stock https://t.co/fAJKfCLGad"  
[X Link](https://x.com/petitnong_/status/2016367651426336789)  2026-01-28T04:28Z [---] followers, [----] engagements


"Data centers are a sector poised for sustained growth in the future. $Iren $msft $IREN x AWS rumors are blazing X buzz: $IREN could announce a massive AI data center deal with Amazon leveraging GW-scale clean power in Texas. Clues: Earnings shifted to Feb [--] (Amazon's day) direct AWS refs by management plus their $9.7B Microsoft win. If real its https://t.co/Wu6zIxgPYd $IREN x AWS rumors are blazing X buzz: $IREN could announce a massive AI data center deal with Amazon leveraging GW-scale clean power in Texas. Clues: Earnings shifted to Feb [--] (Amazon's day) direct AWS refs by management plus"  
[X Link](https://x.com/petitnong_/status/2016449655945740340)  2026-01-28T09:53Z [---] followers, [---] engagements


"I took some time to clear my head today after the shock of seeing the information about ImmunityBiowhich I spent all day researchingstolen by someone on Twitter with just a few clicks. On the bright side thanks to that break I think I'll be able to successfully add to my position at today's lows. Now that Ive finished gathering my thoughts Ill be back soon with even better information for all of you. $ibrx"  
[X Link](https://x.com/petitnong_/status/2016616871911637456)  2026-01-28T20:58Z [---] followers, [----] engagements


"In May [----] Patrick Soon-Shiong the Executive Chairman of ImmunityBio visited Saudi Arabia as a member of the U.S. economic delegation coinciding with President Donald Trump's state visit to the country. During this visit alongside other prominent business leaders such as Sam Altman (CEO of OpenAI) and Elon Musk (CEO of Tesla) Dr. Soon-Shiong met with the Saudi Crown Prince and de facto leader Mohammed bin Salman (MBS) at the Riyadh Palace. On this occasion ImmunityBio signed a strategic Memorandum of Understanding (MOU) with the Saudi Ministry of Investment (MISA) and other entities to"  
[X Link](https://x.com/petitnong_/status/2016649702750769289)  2026-01-28T23:08Z [---] followers, [----] engagements


"In February [----] Patrick Soon-Shiong Executive Chairman of ImmunityBio joined an elite delegation of American business leaders accompanying President Trump on his state visit to Saudi Arabia. The economic delegation featured some of the worlds most influential tech figures including OpenAI CEO Sam Altman Tesla CEO Elon Musk and NVIDIA CEO Jensen Huang. President Trump included Patrick Soon-Shiong as a key representative of the U.S. biotechnology sector highlighting ImmunityBio as a company poised to rewrite the history of cancer treatment. @DrPatrick @ImmunityBio $IBRX President Trump and HRH"  
[X Link](https://x.com/petitnong_/status/2016669754862534776)  2026-01-29T00:28Z [---] followers, [----] engagements


"ImmunityBio Building the "BioShield" Ecosystem Beyond ANKTIVA ImmunityBio is advancing a robust pipeline to secure approvals and expand indications across all types of solid tumors. These therapies act as immune accelerators specifically designed to proliferate and activate T cells and NK cells. [--]. hAd5 Cancer Vaccines - IBRX-042: A vaccine specialized for HPV (Human Papillomavirus) targeting head and neck cancer as well as cervical cancer; currently in Phase [--] clinical trials. - IBRX-043 / 044: A common antigen vaccine targeting colorectal and lung cancers currently in Phase 1/2. - Tri-Ad5:"  
[X Link](https://x.com/petitnong_/status/2016810138896912905)  2026-01-29T09:46Z [---] followers, [----] engagements


"I want to accumulate more shares of ImmunityBio. To be honest a short squeeze is not exactly welcome news for a long-term investor. $IBRX #shortsqueeze $IBRX Current market data for ImmunityBio as of January [--] [----] indicates a highly "crowded" short trade. The setup suggests that shorts are currently paying high premiums to hold their positions and the "days to cover" metric is high enough that any significant price jump $IBRX Current market data for ImmunityBio as of January [--] [----] indicates a highly "crowded" short trade. The setup suggests that shorts are currently paying high premiums"  
[X Link](https://x.com/petitnong_/status/2016850623917150315)  2026-01-29T12:27Z [---] followers, [---] engagements


"ImmunityBio is scheduled to present interim Phase [--] data for its Glioblastoma (GBM) clinical trial tomorrow. Venue: Stand Up to Cancer Glioblastoma Innovation Scientific Summit This presentation follows the initial update on January 23rd where the company briefly noted promising progress stating that the median Overall Survival (mOS) has not yet been reached. At this upcoming summit the company is expected to provide a "Deep Dive" into the data including full survival curves and detailed results on reversing lymphopenia. $ibrx @ImmunityBio @DrPatrick"  
[X Link](https://x.com/petitnong_/status/2017116231325929700)  2026-01-30T06:02Z [---] followers, [----] engagements


"As I mentioned yesterday regarding ImmunityBios "BioShield" strategy Dr. Patrick Soon-Shiong also highlighted this in his recent interview. I will continue to provide you with more diverse and in-depth updates on ImmunityBio moving forward. $ibrx @DrPatrick @ImmunityBio Lung cancer. A devastating disease when current standards of care fail . Our Quilt [----] randomized trial in early diagnosed first line patients and Quilt3.005 in patients who failed all standards of care was the basis of accelerated approval by Saudi FDA. The beginning of the Lung cancer. A devastating disease when current"  
[X Link](https://x.com/petitnong_/status/2017117095973310476)  2026-01-30T06:06Z [---] followers, [----] engagements


"Not just a single digit but they bought as much as 18% $ibrx $IBRX Vanguard Group ImmunityBio Largest Institutional Holder Increases Its Stake By 5.1mil Shares In 4Q25 ie +18% Reaching Up 32.7mil Shares Overall. https://t.co/ENjE2uuvyr $IBRX Vanguard Group ImmunityBio Largest Institutional Holder Increases Its Stake By 5.1mil Shares In 4Q25 ie +18% Reaching Up 32.7mil Shares Overall. https://t.co/ENjE2uuvyr"  
[X Link](https://x.com/petitnong_/status/2017419517274820761)  2026-01-31T02:07Z [---] followers, [----] engagements


"The New Jersey Division of Investment has recently taken a position in ImmunityBio $IBRX While the initial investment amount may be relatively small institutional moves like this often signal the beginning of a larger trend that can lead to significant long-term gains. @ImmunityBio @DrPatrick $IBRX NEWS ☕🗞 State of New Jersey Common Pension Fund D filed a 13F-HR form disclosing ownership of [------] shares of @ImmunityBio https://t.co/JnCBq7QAs3 https://t.co/2LtGIjq8sS $IBRX NEWS ☕🗞 State of New Jersey Common Pension Fund D filed a 13F-HR form disclosing ownership of [------] shares of"  
[X Link](https://x.com/petitnong_/status/2017766937590436265)  2026-02-01T01:08Z [---] followers, [----] engagements


"Expansion of Immunotherapy When I first learned about ImmunityBio and read Dr. Soon-Shiong's SNS with my family I vaguely felt that he wasn't just trying to create a cancer treatment. Back then I didn't have a clear image but I could sense that he was designing an enormous project. ANKTIVA is just the beginning. He is drawing a much bigger picture. When I first started investing I didn't know exactly what it was but I knew a massive project was being outlined. I decided to invest after much deliberation even though the specifics hadn't been revealed yet because I could see the confidence."  
[X Link](https://x.com/petitnong_/status/2017771727888298418)  2026-02-01T01:27Z [---] followers, [----] engagements


"There is no need to conduct separate clinical trials in each country when expanding into the Middle East. This is especially true for a company like ImmunityBio which has already secured approval from Saudi Arabia's SFDA; such a foundation allows the expansion into other Middle Eastern nations to proceed very efficiently. The announcements at the World Health Expo in Dubai this February are likely to focus on distribution and sales agreements with neighboring countries leveraging Saudi Arabia's existing approval data rather than on new clinical trial plans. $ibrx @ImmunityBio @DrPatrick"  
[X Link](https://x.com/petitnong_/status/2017774422325924234)  2026-02-01T01:38Z [---] followers, [----] engagements


"$tenn next $toyo Number of shares redeemed: 2769808"  
[X Link](https://x.com/petitnong_/status/1821182473809846370)  2024-08-07T13:51Z [---] followers, [---] engagements


"$ibrx Immunitybio Inc Regarding CAR-NK let me add some further explanation. The core principle of ImmunityBios Anktiva is injecting IL-15 cells that allow NK cells (a type of immune cell) to be produced in greater quantities survive longer and remain in a more activated state. However the problem with cancer cells is their ability to disguise themselves so that immune cells cannot recognize them. Therefore simply increasing the number of NK cells has limited efficacy. This is why Anktiva is used in combination therapy with Immune Checkpoint Inhibitors like Keytruda (which remove the cancer's"  
[X Link](https://x.com/petitnong_/status/2014693149709631682)  2026-01-23T13:34Z [----] followers, [----] engagements


"ImmunityBio's ANKTIVA is evolving beyond a simple treatment into a national-scale project. According to a recently released video Dr. Patrick Soon-Shiong met with the Saudi SFDA and key medical leadership to share a new oncology paradigm focused on protecting lymphocytes. This initiative is being driven as part of "health diplomacy" based on a shared vision between the leaders of the United States and Saudi Arabia. Key [----] Timeline - Early February: Final decision on European Commission (EC) approval for ANKTIVA. - February 912: Expected announcement of Middle East market expansion at the"  
[X Link](https://x.com/petitnong_/status/2017773637361926473)  2026-02-01T01:34Z [---] followers, [----] engagements


"Even the most breakthrough drugs remain out of reach for patients if they aren't covered by insurance. Since its release ANKTIVA has established a robust market access framework covering more than [---] million medical lives ensuring that patients can access treatment without prohibitive out-of-pocket costs. This extensive insurance network is a primary driver behind ANKTIVAs rapid market adoption and accelerated revenue growth $ibrx @ImmunityBio @DrPatrick https://twitter.com/i/web/status/2017926195590180891 https://twitter.com/i/web/status/2017926195590180891"  
[X Link](https://x.com/petitnong_/status/2017926195590180891)  2026-02-01T11:41Z [---] followers, [----] engagements


"4   .       . [--]. (TPD)    - $GLUE $CCCC [--]. (ADC)     - $ADCT $PYXS $STRO   [--]  .   . https://twitter.com/i/web/status/2009608752161521714 https://twitter.com/i/web/status/2009608752161521714"  
[X Link](https://x.com/petitnong_/status/2009608752161521714)  2026-01-09T12:50Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing